MARKET

BOLT

BOLT

Bolt Biotherapeutics, Inc.
NASDAQ
4.500
+0.210
+4.90%
Closed 19:56 03/26 EDT
OPEN
4.480
PREV CLOSE
4.500
HIGH
4.500
LOW
4.370
VOLUME
1.82K
TURNOVER
122.51K
52 WEEK HIGH
9.66
52 WEEK LOW
3.910
MARKET CAP
8.65M
P/E (TTM)
-0.2521
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at BOLT last week (0316-0320)?
Weekly Report · 3d ago
Wall Street Analysts Are Bullish on Top Healthcare Picks
TipRanks · 03/17 08:50
Weekly Report: what happened at BOLT last week (0309-0313)?
Weekly Report · 03/16 09:28
Buy Rating on Bolt Biotherapeutics Driven by Differentiated Claudin 18.2 ISAC BDC-4182 and Solid Cash Runway to 2027
TipRanks · 03/13 10:25
Bolt Biotherapeutics Price Target Maintained With a $7.00/Share by HC Wainwright & Co.
Dow Jones · 03/13 10:20
HC Wainwright & Co. Reiterates Buy on Bolt Biotherapeutics, Maintains $7 Price Target
Benzinga · 03/13 10:12
Bolt Biotherapeutics Q4 loss narrows as expenses fall
Reuters · 03/12 20:58
Bolt Biotherapeutics reports Q4 EPS ($3.84), consensus ($5.52)
TipRanks · 03/12 20:31
More
About BOLT
Bolt Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company developing immunotherapies for the treatment of cancer. The Company’s pipeline includes BDC-3042, an agonist antibody that activates macrophages by targeting dectin-2, and BDC-4182, a next generation Boltbody Immune-Stimulating Antibody Conjugate (ISAC) clinical candidate targeting claudin 18.2. BDC-3042 is in a Phase I dose escalation trial that includes patients with any of seven different solid tumor types. The Company’s Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. It has two additional ISAC programs utilizing its Boltbody ISAC technology platform in preclinical development. One is a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5 (CEA). Its final Boltbody ISAC program targets PD-L1. The Company is also developing additional Boltbody ISACs in strategic collaborations with biopharmaceutical companies.

Webull offers Bolt Biotherapeutics Inc stock information, including NASDAQ: BOLT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BOLT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BOLT stock methods without spending real money on the virtual paper trading platform.